Company / Operating Cash Flow
Tarsus Pharmaceuticals, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$12.5M
FY2025
5-year range
-$117.5M / $3.7M
FY2021-FY2025
Trend
+85.0%
vs FY2024
Sector context
#82 of 216
Health Care
What the data says
At -$12M, Tarsus Pharmaceuticals, Inc.'s operating cash flow ranks #82 of 216 in the Health Care sector. Improved from -$117M to -$12M over the past 2 years.
Based on SEC 10-K filings.
-$12M in FY2025.
Improved from -$117M to -$12M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#82 of 216 in Health CareTop 38% of 216This company -$12.5M Sector average $658.7M
▼
-101.9% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 85.0% year-over-year.
- Ranks #82 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$12.5M | +85.0% |
| FY2024 | -$83.0M | +29.3% |
| FY2023 | -$117.5M | -3234.8% |
| FY2022 | $3.7M | +0.0% |
| FY2021 | $3.7M | +117.7% |
| FY2020 | -$21.1M | -475.5% |
| FY2019 | -$3.7M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026